Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology Forecast Report Coverage

Expert Market Research's “Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of ankylosing spondylitis (Bekhterev’s disease). It projects the future incidence and prevalence rates of ankylosing spondylitis (Bekhterev’s disease) cases across various populations. The study covers age, gender, and type as major determinants of the ankylosing spondylitis (Bekhterev’s disease) population. The report highlights patterns in the prevalence of ankylosing spondylitis (Bekhterev’s disease) over time and projects future trends based on multiple variables.

Ankylosing Spondylitis (Bekhterev’s Disease) Understanding: Disease Overview

Ankylosing spondylitis (AS), historically referred to as Bekhterev's disease, is a chronic, systemic inflammatory disorder primarily affecting the axial skeleton. Inflammation characteristically begins at the sacroiliac joints and can ascend through the lumbar and thoracic spine to the cervical region. Prolonged, uncontrolled inflammation leads to new bone formation, potentially causing vertebral fusion, decreased spinal mobility, and a characteristic stooped posture. Beyond the axial skeleton, AS can involve peripheral joints, the eyes (uveitis), cardiovascular structures, and the gastrointestinal tract. The disease is strongly associated with the HLA-B27 genetic marker, present in approximately 90% of affected individuals in White populations and typically manifests in late adolescence or early adulthood. Males are more frequently diagnosed, though the introduction of MRI-based diagnostic criteria has improved detection in females and non-radiographic cases.

Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology Perspective

The ankylosing spondylitis (Bekhterev’s disease) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for ankylosing spondylitis (Bekhterev’s disease) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for ankylosing spondylitis (Bekhterev’s disease) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to ankylosing spondylitis epidemiological observations reported by Gasteiner Heilstollen, the disease commonly begins in early adulthood. Initial symptoms typically appear between 15 and 35 years of age; however, diagnosis frequently occurs later when disease progression becomes more apparent, leading to delayed clinical identification despite early onset.
• According to Ajanee Mahakkanukrauh et al., 2024, incidence patterns indicate comparable gender distribution. In 2017, females recorded 22.4 cases per 100,000 person-years compared with 18.3 among males, while similar trends persisted in 2018 (11.8 vs. 8.9), 2019 (11.6 vs. 9.1), and 2020 (11.7 vs. 9.0).
• According to Malini Alexander et al., 2023, global epidemiology is strongly influenced by the presence of the HLA-B27 genetic marker. Approximately 10–16% of Norwegians, Swedes, and Icelanders carry HLA-B27, while prevalence increases to 25–50% among Inuit, Yupik, and Indigenous Northern American populations.
• As per Malini Alexander et al., 2023, ethnicity significantly affects disease prevalence and severity. Ankylosing spondylitis is nearly three times less common in American Black populations than in White populations and is extremely rare among African Black populations of unmixed ancestry.
• According to Malini Alexander et al., 2023, the HLA-B27 antigen is present in more than 80% of White patients with ankylosing spondylitis but in less than 60% of American Black patients. It occurs in about 62.5% of African Americans, 85.3% of White Americans, and 86.7% of Latino Americans, with higher disease activity reported in African American populations.

Read more about this report - Request a Free Sample

Country-wise Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology

The ankylosing spondylitis (Bekhterev’s disease) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Epidemiological patterns of ankylosing spondylitis (Bekhterev’s disease) vary across major healthcare regions but consistently indicate a measurable disease burden. According to Mayur Sharma et al., 2022, the prevalence of ankylosing spondylitis in the United States is estimated at approximately 0.5%–1%, with a higher occurrence in males. In Europe, as per Kristina Berr et al., 2023, Germany reports a prevalence of about 0.3%–0.5%, with an average diagnostic delay of nearly seven years and a significant proportion of undiagnosed cases. Overall, epidemiological findings across the United Kingdom, France, Spain, Italy, Japan, and India indicate ongoing challenges in early diagnosis and accurate estimation of disease burden across regions.

Ankylosing Spondylitis (Bekhterev’s Disease): Treatment Overview

Treatment of ankylosing spondylitis is aimed at reducing inflammation, relieving pain, and preserving spinal mobility. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first-line pharmacological option, providing symptomatic relief and potentially slowing radiographic progression in sustained users. For patients with inadequate NSAID response, biologic therapies, primarily tumor necrosis factor (TNF) inhibitors such as adalimumab, etanercept, and infliximab—have transformed disease management. More recently, interleukin-17A (IL-17A) inhibitors, including secukinumab and ixekizumab, have demonstrated robust efficacy in active AS. Janus kinase (JAK) inhibitors, notably tofacitinib, received regulatory approval for AS in patients with inadequate TNF-inhibitor response. Non-pharmacological management, including physiotherapy, hydrotherapy, and structured exercise programs, is integral to maintaining function and quality of life.

Key Questions Answered

• What are the key findings of ankylosing spondylitis (Bekhterev’s disease) epidemiology in the 8 major markets?
• What will be the total number of patients with ankylosing spondylitis (Bekhterev’s disease) across the 8 major markets during the forecast period?
• What was the country-wise ankylosing spondylitis (Bekhterev’s disease) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of ankylosing spondylitis (Bekhterev’s disease) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of ankylosing spondylitis (Bekhterev’s disease) during the forecast period of 2026-2035?
• What are the currently available treatments for ankylosing spondylitis (Bekhterev’s disease)?
• What are the risks, signs, symptoms, and unmet needs of ankylosing spondylitis (Bekhterev’s disease)?

Scope of the Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of ankylosing spondylitis (Bekhterev’s disease) based on several factors.
• Ankylosing Spondylitis (Bekhterev’s Disease) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The ankylosing spondylitis (Bekhterev’s disease) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Analysis Report

Ankylosing Spondylitis Treatment Market